Company Registry

Quad Pharmaceuticals
Profile last edited on: 8/7/2012

NO Business Identifier is currently available for this company.
Year Founded
First SBIR Year
Latest SBIR Award
Program Status
Inactive (Acquired)


Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

6340 La Pas Trail
Indianapolis, IN 46268
   (317) 299-6611
Multiple Locations:   
Congressional District:   05
County:   Marion

Public Profile

Quad Pharmaceuticals was absorbed within Par Pharmaceutical, Inc., which is now itself a wholly owned subsidiary of Pharmaceutical Resources, Inc. The latter is a manufacturer and distributor of a broad line of generic drugs. The Company's product line consists of prescription and over the counter products marketed principally in solid oral dosage form consisting of tablets, caplets and two-piece hard-shell capsules. In addition, the Company markets a product in the semi-solid form of a cream. Par's executive offices, part of its research and development center and a substantial portion of its production facilities are located in Spring Valley, New York. The Company markets its products primarily to drug wholesalers, retail drug chains, repackagers, distributors and government agencies. In addition, the Company is increasing its sales and marketing efforts in the managed health care market which includes health maintenance organizations, nursing homes, hospitals, clinics, pharmacy benefit management companies and mail order facilities. The firm's primary R&D activities consist of identifying and conducting patent and market research on brand name drugs for which patent protection has expired or is to expire in the near future, researching and developing new product formulations based upon such drugs, obtaining approval from the FDA for such new product formulations, and introducing technology to improve production efficiency and enhance product quality. Par began business operations in 1979. In 1983, the Company filed an initial public offering, and in 1987 began listing the Company's stock (PRX) on the New York Stock Exchange

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount Project Title
1986 1 NIH $50,000
Development of emulsified lipoid contrast media selective opacification of liver

Key People / Management

  Dulal Chatterji --

SBIR firms in the news

There are no news available.